CLASS III Drug recall · Reported 15 Jan 2014 · FDA Enforcement Report

Fenofibric Acid, immediate release tablet, 105 mg, a) bottle recalled

Mutual Pharmaceutical is recalling Fenofibric Acid, immediate release tablet, 105 mg, a) bottle (, distributed nationwide in the US. The recall was initiated on 27 Feb 2013 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codeslot 6581105 & 6581106 exp. 07/15, and lot 6623001 & 6623002 exp. 01/16

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-400-2014
FDA event ID
64727
Recalling firm
Mutual Pharmaceutical, Philadelphia, PA
Classification
Class III
Status
Terminated
Recall initiated
27 Feb 2013
FDA classified
6 Jan 2014
Reported
15 Jan 2014
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

27 Feb 2013Recall initiated by company
6 Jan 2014Classified by FDA+313 days
15 Jan 2014Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Labeling: Incorrect instructions; an error in section 5.11 of the patient insert that results in incorrect medical advice. Specifically, the labeling should read "If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated." The labeling for the recalled lots

Product as listed by the FDA

Fenofibric Acid, immediate release tablet, 105 mg, a) 30 count bottle (NDC 53489-678-07), b) 90 count bottle (NDC 53489-678-90), Rx only, Mutual Pharmaceutical Co., Inc., Philadelphia, PA 19124 USA

Where it was distributed

Nationwide and Puerto Rico.

Nationwide Puerto Rico

Questions about this recall

Why was it recalled?

Labeling: Incorrect instructions; an error in section 5.11 of the patient insert that results in incorrect medical advice. Specifically, the labeling should read "If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated." The labeling for the recalled lots

Which lots are affected?

lot 6581105 & 6581106 exp. 07/15, and lot 6623001 & 6623002 exp. 01/16

Where was it sold?

Nationwide and Puerto Rico.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

2 other products · FDA event 64727

More recalls from Mutual Pharmaceutical

All 14
ReportedClassRecallCompanyReasonWhere
DrugCLASS IISulfamethoxazole and Trimethoprim Tablets recalledMutual PharmaceuticalOtherMS
DrugCLASS IIIImipramine HCl Tablets, USP, 10 mg recalledMutual PharmaceuticalOtherNationwide
DrugCLASS IIIImipramine HCl Tablets, USP, 25 mg recalledMutual PharmaceuticalOtherNationwide
DrugCLASS IIIImipramine HCl Tablets, USP, 50 mg recalledMutual PharmaceuticalOtherNationwide
DrugCLASS IIIFelodipine Extended-Release Tablets, 5 mg recalledMutual PharmaceuticalOtherNationwide

Other Fenofibric Acid recalls

All 4